MORF
Closed
Morphic Holding Inc
56.99
+0.01 (+0.02%)
Last Update: 16 Aug 2024 16:30:00
Yesterday: 56.985
Day's Range: 56.99 - 56.99
Send
sign up or login to leave a comment!
When Written:
34.33
Morphic Holding Inc is a biopharmaceutical company that focuses on developing oral integrin therapies for the treatment of autoimmune and inflammatory diseases. The company's lead product candidate, MORF-057, is an oral integrin inhibitor that is being developed for the treatment of inflammatory bowel disease (IBD).
Morphic Holding Inc was founded in 2015 and is headquartered in Waltham, Massachusetts. The company went public in 2018 and is listed on the NASDAQ stock exchange under the ticker symbol MORF.
The company's approach to drug development is based on the concept of integrins, which are proteins that play a key role in cell adhesion and signaling. By targeting specific integrins, Morphic Holding Inc believes it can develop therapies that are more effective and have fewer side effects than current treatments for autoimmune and inflammatory diseases.
Morphic Holding Inc has partnerships with several pharmaceutical companies, including AbbVie, Janssen Biotech, and Schrödinger, to develop integrin-based therapies for a range of diseases. The company's management team includes experienced biotech executives and scientists with expertise in drug discovery and development.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Morphic Holding Inc was founded in 2015 and is headquartered in Waltham, Massachusetts. The company went public in 2018 and is listed on the NASDAQ stock exchange under the ticker symbol MORF.
The company's approach to drug development is based on the concept of integrins, which are proteins that play a key role in cell adhesion and signaling. By targeting specific integrins, Morphic Holding Inc believes it can develop therapies that are more effective and have fewer side effects than current treatments for autoimmune and inflammatory diseases.
Morphic Holding Inc has partnerships with several pharmaceutical companies, including AbbVie, Janssen Biotech, and Schrödinger, to develop integrin-based therapies for a range of diseases. The company's management team includes experienced biotech executives and scientists with expertise in drug discovery and development.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








